Ivana Okor
Internal Medicine · Bronx, NYNPI 1396233243
Payments from drug & device makers
Across 67 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$212
- Novo Nordisk$156
- Amgen$150
- Boehringer Ingelheim$129
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
- Lantheus Medical Imaging, Inc.$94
- plus $544 from 14 others
What the payments were for
- Food & beverage$1,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $212 |
| Novo Nordisk | 8 | $156 |
| Amgen | 7 | $150 |
| Boehringer Ingelheim | 7 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $105 |
| Lantheus Medical Imaging, Inc. | 3 | $94 |
| Pfizer | 5 | $85 |
| AstraZeneca | 4 | $68 |
| Bayer | 3 | $58 |
| Johnson & Johnson | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Abiomed | 1 | $35 |
| Merck | 1 | $24 |
| Heartflow, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
How this compares
$1,391 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 60 | $56,687 |
| EntrestoSacubitril/Valsartan | 30 | $23,079 |
| JardianceEmpagliflozin | 12 | $15,575 |
| Metoprolol Succinate | 51 | $1,100 |
| Atorvastatin Calcium | 37 | $678 |
| Valsartan | 22 | $600 |
| Carvedilol | 34 | $274 |
| Amlodipine Besylate | 16 | $167 |
| Spironolactone | 16 | $154 |
| Lisinopril | 11 | $104 |
| Metoprolol Tartrate | 16 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $56,68760 claims |
| NovartisEntresto | $212 | $23,07930 claims |
| Boehringer IngelheimJardiance | $129 | $15,57512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.